FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114280388> ?p ?o ?g. }

• W2114280388 abstract "Background Approved US indications for trastuzumab include adjuvant treatment of HER2−overexpressing breast cancer in anthracycline-based (ACTH) or non-anthracycline-based (TCH) regimens. The objective of this study was to compare trastuzumab persistence across adjuvant breast cancer treatment regimens for US health plan enrollees. Materials and Methods : This retrospective cohort study using the IMS LifeLink™ Health Plan Claims Database included adjuvant breast cancer patients, defined as those with a mastectomy or lumpectomy and a primary breast cancer diagnosis (index diagnosis) from 1/1/2006 to 12/31/2008. Additional inclusion criteria were: aged ≥18 years; a second primary breast cancer diagnosis ≤90 days of the first; no other primary or secondary neoplasms ≤180 days before or ≤90 days after the index diagnosis; a first trastuzumab claim (index claim) and ≥1 carboplatin, cyclophosphamide, taxane, or anthracycline claim ≤210 days of the index diagnosis; and no trastuzumab claim before the index diagnosis. Regimens were classified as ACTH (doxorubicin, cyclophosphamide, a taxane, trastuzumab) or TCH (docetaxel, carboplatin, trastuzumab) from therapies observed after the index claim. Trastuzumab persistence (days from the index claim to earliest of trastuzumab discontinuation, a new malignant neoplasm, end of plan enrollment, 360 days after the index claim, or end of available data) was reported for patients with ≥2 trastuzumab claims and compared across regimens using the Kaplan-Meier estimator and Cox proportional hazards models. Results : 550 breast cancer patients met all study criteria (291 ACTH, 259 TCH, 46 unassigned); patients receiving TCH were older (median 52 vs. 50 years; P=0.018). For years 2006–2008, the annual share of the cohort initiating ACTH decreased from 69.3% to 35.2%; patients initiating TCH increased from 26.7% to 56.5%. Patients receiving ACTH were treated with trastuzumab for fewer days (mean=256, median=334) versus patients on TCH (mean=282, median 344, P=0.018). Fewer patients on ACTH remained on trastuzumab at day 90 (83% vs. 91%), day 180 (71% vs. 79%), day 270 (61% vs. 72%), and day 360 (20% vs. 26%). Compared to patients on TCH, patients on ACTH continued to be treated with trastuzumab for a shorter duration post-index after adjusting for age, region, plan type, prescriber specialty, and comorbidities (HR=0.77, 95% CI [0.63, 0.95]; P=0.016). Discussion : The share of adjuvant breast cancer patients initiating TCH increased from 2006 to 2008, while use of ACTH decreased over the same time period, and patients treated with TCH remained on trastuzumab for a longer period of time. From a clinical standpoint, patients derive maximum benefit from their medications when they are persistent long-term, which can lead to economic benefits with regards to lower overall healthcare costs. Further analyses will evaluate whether adjuvant breast cancer regimens differ in weight-adjusted cumulative trastuzumab doses received during therapy. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-18-08." @default.
• W2114280388 created "2016-06-24" @default.
• W2114280388 creator A5019132733 @default.
• W2114280388 creator A5039663370 @default.
• W2114280388 creator A5049462886 @default.
• W2114280388 creator A5065830650 @default.
• W2114280388 creator A5072015843 @default.
• W2114280388 date "2011-12-15" @default.
• W2114280388 modified "2023-09-27" @default.
• W2114280388 title "P5-18-08: A Comparative Effectiveness Analysis of Trastuzumab Persistence between Two Adjuvant Breast Cancer Treatment Regimens among US Health Plan Enrollees." @default.
• W2114280388 doi "https://doi.org/10.1158/0008-5472.sabcs11-p5-18-08" @default.
• W2114280388 hasPublicationYear "2011" @default.
• W2114280388 type Work @default.
• W2114280388 sameAs 2114280388 @default.
• W2114280388 citedByCount "0" @default.
• W2114280388 crossrefType "proceedings-article" @default.
• W2114280388 hasAuthorship W2114280388A5019132733 @default.
• W2114280388 hasAuthorship W2114280388A5039663370 @default.
• W2114280388 hasAuthorship W2114280388A5049462886 @default.
• W2114280388 hasAuthorship W2114280388A5065830650 @default.
• W2114280388 hasAuthorship W2114280388A5072015843 @default.
• W2114280388 hasConcept C121608353 @default.
• W2114280388 hasConcept C126322002 @default.
• W2114280388 hasConcept C143998085 @default.
• W2114280388 hasConcept C2776694085 @default.
• W2114280388 hasConcept C2776802502 @default.
• W2114280388 hasConcept C2777511904 @default.
• W2114280388 hasConcept C2778239845 @default.
• W2114280388 hasConcept C2779786085 @default.
• W2114280388 hasConcept C2781451048 @default.
• W2114280388 hasConcept C530470458 @default.
• W2114280388 hasConcept C71924100 @default.
• W2114280388 hasConceptScore W2114280388C121608353 @default.
• W2114280388 hasConceptScore W2114280388C126322002 @default.
• W2114280388 hasConceptScore W2114280388C143998085 @default.
• W2114280388 hasConceptScore W2114280388C2776694085 @default.
• W2114280388 hasConceptScore W2114280388C2776802502 @default.
• W2114280388 hasConceptScore W2114280388C2777511904 @default.
• W2114280388 hasConceptScore W2114280388C2778239845 @default.
• W2114280388 hasConceptScore W2114280388C2779786085 @default.
• W2114280388 hasConceptScore W2114280388C2781451048 @default.
• W2114280388 hasConceptScore W2114280388C530470458 @default.
• W2114280388 hasConceptScore W2114280388C71924100 @default.
• W2114280388 hasLocation W21142803881 @default.
• W2114280388 hasOpenAccess W2114280388 @default.
• W2114280388 hasPrimaryLocation W21142803881 @default.
• W2114280388 isParatext "false" @default.
• W2114280388 isRetracted "false" @default.
• W2114280388 magId "2114280388" @default.
• W2114280388 workType "article" @default.